We report the successful and safe use of levosimendan, a new calcium-sensitizing agent with positive inotropic and vasodilatory action, in 2 critically ill term newborns with acute heart failure and pulmonary hypertension in the absence of any underlying heart malformation and/or previous cardiosurgical procedures. During the neonatal period, levosimendan may represent an ideal drug for immature myocardium characterized by a higher calcium-dependent contractility than in adults.
De Carolis, M. P., Piastra, M., Bersani, I., Pardeo, M., Stival, E., Tempera, A., Romagnoli, C., Conti, G., De Rosa, G., Levosimendan in two neonates with ischemic heart failure and pulmonary hypertension., <<NEONATOLOGY>>, 2012; 101 (3): 201-205. [doi:10.1159/000329848] [http://hdl.handle.net/10807/36716]
Levosimendan in two neonates with ischemic heart failure and pulmonary hypertension.
De Carolis, Maria Pia;Piastra, Marco;Bersani, Iliana;Pardeo, Manuela;Stival, Eleonora;Romagnoli, Costantino;Conti, Giorgio;De Rosa, Gabriella
2012
Abstract
We report the successful and safe use of levosimendan, a new calcium-sensitizing agent with positive inotropic and vasodilatory action, in 2 critically ill term newborns with acute heart failure and pulmonary hypertension in the absence of any underlying heart malformation and/or previous cardiosurgical procedures. During the neonatal period, levosimendan may represent an ideal drug for immature myocardium characterized by a higher calcium-dependent contractility than in adults.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
